207_Combined course Presentations

Alternative drugs: Bevacizumab (RTOG 0825)

Median OS 15.7 vs 16.1 months

Median PFS 10.7 vs 7.3 months

 First-line use of Bevacizumab did not improve OS  PFS was prolonged, but did not reach the prespecifiec improvement target (-30% reduction )

Gilbert MR. et al. NEJM 2014:370